- Home
- GDTC vs MIRA Comparison
GDTC vs MIRA Comparison
Compare GDTC & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDTC
- MIRA
- Stock Information
- Founded
- GDTC 2018
- MIRA 2020
- Country
- GDTC Singapore
- MIRA United States
- Employees
- GDTC N/A
- MIRA N/A
- Industry
- GDTC Biotechnology: Pharmaceutical Preparations
- MIRA Biotechnology: Pharmaceutical Preparations
- Sector
- GDTC Health Care
- MIRA Health Care
- Exchange
- GDTC Nasdaq
- MIRA Nasdaq
- Market Cap
- GDTC 22.9M
- MIRA 26.5M
- IPO Year
- GDTC 2023
- MIRA 2023
- Fundamental
- Price
- GDTC $1.90
- MIRA $1.38
- Analyst Decision
- GDTC Buy
- MIRA Strong Buy
- Analyst Count
- GDTC 1
- MIRA 1
- Target Price
- GDTC $5.00
- MIRA $17.00
- AVG Volume (30 Days)
- GDTC 9.9K
- MIRA 198.7K
- Earning Date
- GDTC 01-01-0001
- MIRA 08-14-2025
- Dividend Yield
- GDTC N/A
- MIRA N/A
- EPS Growth
- GDTC N/A
- MIRA N/A
- EPS
- GDTC N/A
- MIRA N/A
- Revenue
- GDTC $368,838.00
- MIRA N/A
- Revenue This Year
- GDTC $5.37
- MIRA N/A
- Revenue Next Year
- GDTC N/A
- MIRA N/A
- P/E Ratio
- GDTC N/A
- MIRA N/A
- Revenue Growth
- GDTC N/A
- MIRA N/A
- 52 Week Low
- GDTC $1.20
- MIRA $0.73
- 52 Week High
- GDTC $4.05
- MIRA $2.56
- Technical
- Relative Strength Index (RSI)
- GDTC 48.17
- MIRA 43.25
- Support Level
- GDTC $1.85
- MIRA $1.35
- Resistance Level
- GDTC $2.07
- MIRA $1.42
- Average True Range (ATR)
- GDTC 0.08
- MIRA 0.06
- MACD
- GDTC 0.02
- MIRA -0.00
- Stochastic Oscillator
- GDTC 51.12
- MIRA 14.29
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.